Firm Blocks Abortion Pill, FDA Chief Says
FDA Commissioner David A. Kessler accused a German drug company Thursday of blocking its French subsidiary from seeking to market the abortion pill RU-486 in the United States.
Kessler said the problem was not with the French company, Roussel-Uclaf, but its parent, Hoechst AG, and chairman, Wolfgang Hilger.
Kessler, who met with Roussel-Uclaf’s president in February, said: “My understanding is Roussel certainly is willing to bring this drug to this country. It’s the German parent.”
“Prof. Hilger is the one. . . . That’s where the problem is,” Kessler told a group of health reporters.
A call to a spokesman at Hoechst AG headquarters in Frankfurt, Germany, was not answered.
Andrea Stine, a spokeswoman for Hoechst Celanese Corp. and Hoechst-Roussel Pharmaceuticals in Somerville, N.J., said they were not involved in making or marketing the drug, and she could not speak for the parent German company.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
